Johnson & Johnson Company Profile (NYSE:JNJ)

About Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson logoJohnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NYSE:JNJ
  • CUSIP: 47816010
  • Web:
  • Market Cap: $352.65 billion
  • Outstanding Shares: 2,683,999,000
Average Prices:
  • 50 Day Moving Avg: $132.79
  • 200 Day Moving Avg: $129.43
  • 52 Week Range: $109.32 - $137.08
  • Trailing P/E Ratio: 22.23
  • Foreward P/E Ratio: 17.00
  • P/E Growth: 2.90
Sales & Book Value:
  • Annual Revenue: $72.53 billion
  • Price / Sales: 4.86
  • Book Value: $26.78 per share
  • Price / Book: 4.91
  • Annual Dividend: $3.36
  • Dividend Yield: 2.5%
  • EBIDTA: $25.15 billion
  • Net Margins: 22.52%
  • Return on Equity: 26.76%
  • Return on Assets: 13.19%
  • Debt-to-Equity Ratio: 0.38%
  • Current Ratio: 1.34%
  • Quick Ratio: 1.01%
  • Average Volume: 5.35 million shs.
  • Beta: 0.79
  • Short Ratio: 2.41

Frequently Asked Questions for Johnson & Johnson (NYSE:JNJ)

What is Johnson & Johnson's stock symbol?

Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."

How often does Johnson & Johnson pay dividends? What is the dividend yield for Johnson & Johnson?

Johnson & Johnson declared a quarterly dividend on Monday, July 17th. Investors of record on Tuesday, August 29th will be paid a dividend of $0.84 per share on Tuesday, September 12th. This represents a $3.36 dividend on an annualized basis and a yield of 2.56%. The ex-dividend date of this dividend is Friday, August 25th. View Johnson & Johnson's Dividend History.

How were Johnson & Johnson's earnings last quarter?

Johnson & Johnson (NYSE:JNJ) issued its quarterly earnings results on Tuesday, July, 18th. The company reported $1.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.79 by $0.04. The firm earned $18.84 billion during the quarter, compared to analysts' expectations of $18.94 billion. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The firm's revenue for the quarter was up 1.9% compared to the same quarter last year. During the same period last year, the business earned $1.74 earnings per share. View Johnson & Johnson's Earnings History.

When will Johnson & Johnson make its next earnings announcement?

Johnson & Johnson is scheduled to release their next quarterly earnings announcement on Tuesday, October, 17th 2017. View Earnings Estimates for Johnson & Johnson.

What guidance has Johnson & Johnson issued on next quarter's earnings?

Johnson & Johnson issued an update on its FY17 earnings guidance on Tuesday, July, 18th. The company provided earnings per share (EPS) guidance of $7.12-7.22 for the period, compared to the Thomson Reuters consensus estimate of $7.11. The company issued revenue guidance of $75.8-76.1 billion, compared to the consensus revenue estimate of $75.65 billion.

Where is Johnson & Johnson's stock going? Where will Johnson & Johnson's stock price be in 2017?

17 equities research analysts have issued twelve-month price objectives for Johnson & Johnson's stock. Their forecasts range from $110.00 to $148.00. On average, they anticipate Johnson & Johnson's share price to reach $134.00 in the next year. View Analyst Ratings for Johnson & Johnson.

What are analysts saying about Johnson & Johnson stock?

Here are some recent quotes from research analysts about Johnson & Johnson stock:

  • 1. According to Zacks Investment Research, "J&J reported mixed Q2 results, beating on earnings but missing on sales. Sales in J&J’s domestic Pharma segment have decelerated this year as a number of key growth drivers like Remicade and Concerta are facing competition. However, J&J is optimistic that sales growth will accelerate in 2H17. We believe that new products including Xarelto, Stelara, Darzalex, and Imbruvica remain the key to growth.  Meanwhile, share buybacks and the restructuring initiative should provide bottom-line support. J&J is also making rapid progress with its pipeline and line extensions. The Actelion buy adds an attractive new therapeutic area – PAH. J&J’s shares have outperformed the large-cap pharma industry this year so far. However, headwinds like negative currency movement, generics, pricing pressure and soft global market conditions remain. Sluggish growth in the Consumer segment due to category slowdown is also a concern." (7/31/2017)
  • 2. BTIG Research analysts commented, "Yesterday, we attended JNJ’s Pharma day held in New Brunswick, NJ. The overarching theme of the day was the expectation that the Pharma business outgrows the IMS projected ~5% 5-year CAGR for branded drugs. Our model is significantly below such expectations, as we have reported growth of ~6.5% during 2017 falling to ~3.6% in 2018 and essentially flat through 2020. Our numbers may prove conservative given that we do not currently include new drug launches of esketamine, guselkumab and sirukumab. We remain Neutral, as we think that the Oncology landscape is becoming more complicated and the Immunology portfolio may underperform internal expectations as a new class of oral drugs comes to market." (5/21/2017)
  • 3. UBS AG analysts commented, "After making appropriate adjustments for year-over-year shipping day differences, JNJ's Q4 sales were up an impressive 9.5% in the U.S., and up 7.6% CC WW. Initial 2017 outlook calls for sales of $74.1-74.8 bil (up 4-5% CC) and EPS of $6.93-7.08 (including the AMO deal). As previewed, the guided range reflects greater impact from FX, and by our estimation a degree of conservatism. Given the continued strong growth of key Pharma franchises, management's potential to drive stable to improving margins, the ~$2.5 bil remaining repurchase authorization and other factors, we see flex and potential upside to management's initial 2017 outlook. We reiterate our Buy rating on top large-cap diversified pick JNJ, trimming our target from $142 to $141 due primarily to the ~$4.3 bil cash outlay for AMO, expected to close in 1Q17." (1/25/2017)
  • 4. Jefferies Group LLC analysts commented, "With biosimilars and generics expected to drag the next few years, we expect JNJ will continue look to M&A to augment growth. Whilst this should ultimately drive better growth, we believe that investors will not reward the shares for this initially." (1/5/2017)

Who are some of Johnson & Johnson's key competitors?

Who are Johnson & Johnson's key executives?

Johnson & Johnson's management team includes the folowing people:

  • Alex Gorsky, Chairman of the Board, Chief Executive Officer
  • Dominic J. Caruso, Chief Financial Officer, Executive Vice President
  • Peter M. Fasolo Ph.D., Chief Human Resource Officer, Executive Vice President
  • Paulus A. Stoffels, Executive Vice President, Chief Scientific Officer
  • Michael H. Ullmann, Executive Vice President, General Counsel
  • Joaquin Duato, Executive Vice President, Worldwide Chairman - Pharmaceuticals
  • Jorge S. Mesquita, Executive Vice President, Worldwide Chairman - Consumer
  • Sandra E. Peterson, Executive Vice President - Group Worldwide Chairman
  • Joseph Wolk, Vice President - Investor Relations
  • Anne M. Mulcahy, Lead Independent Director

Who owns Johnson & Johnson stock?

Johnson & Johnson's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (7.47%), BlackRock Inc. (6.46%), State Street Corp (5.87%), State Farm Mutual Automobile Insurance Co. (1.41%), Bank of New York Mellon Corp (1.35%) and Northern Trust Corp (1.28%). Company insiders that own Johnson & Johnson stock include Charles Prince, Dominic J Caruso, Gary J Pruden, Paulus Stoffels, Peter Fasolo and Ronald A Kapusta. View Institutional Ownership Trends for Johnson & Johnson.

Who sold Johnson & Johnson stock? Who is selling Johnson & Johnson stock?

Johnson & Johnson's stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Boston Partners, Karp Capital Management Corp, Nordea Investment Management AB, APG Asset Management N.V., Renaissance Technologies LLC, Bank of New York Mellon Corp and Robeco Institutional Asset Management B.V.. Company insiders that have sold Johnson & Johnson stock in the last year include Dominic J Caruso and Paulus Stoffels. View Insider Buying and Selling for Johnson & Johnson.

Who bought Johnson & Johnson stock? Who is buying Johnson & Johnson stock?

Johnson & Johnson's stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Janus Henderson Group PLC, Vanguard Group Inc., Parametric Portfolio Associates LLC, Harbour Capital Advisors LLC, FMR LLC, Schroder Investment Management Group and Principal Financial Group Inc.. View Insider Buying and Selling for Johnson & Johnson.

How do I buy Johnson & Johnson stock?

Shares of Johnson & Johnson can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Johnson & Johnson's stock price today?

One share of Johnson & Johnson stock can currently be purchased for approximately $131.39.

MarketBeat Community Rating for Johnson & Johnson (NYSE JNJ)
Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  471 (Vote Outperform)
Underperform Votes:  567 (Vote Underperform)
Total Votes:  1,038
MarketBeat's community ratings are surveys of what our community members think about Johnson & Johnson and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Johnson & Johnson (NYSE:JNJ) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Sell Ratings, 6 Hold Ratings, 7 Buy Ratings
Consensus Rating:Hold (Score: 2.18)
Consensus Price Target: $134.00 (1.99% upside)

Analysts' Ratings History for Johnson & Johnson (NYSE:JNJ)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/20/2017Goldman Sachs Group, Inc. (The)DowngradeNeutral -> Sell$125.00 -> $130.00LowView Rating Details
9/1/2017BMO Capital MarketsReiterated RatingBuy$145.00N/AView Rating Details
8/24/2017Cowen and CompanySet Price TargetBuy$147.00LowView Rating Details
8/15/2017Jefferies Group LLCSet Price TargetHold$145.00LowView Rating Details
8/16/2017J P Morgan Chase & CoBoost Price TargetOverweight$140.00 -> $148.00LowView Rating Details
8/4/2017Credit Suisse GroupReiterated RatingBuyLowView Rating Details
7/21/2017Alembic Global AdvisorsDowngradeNeutral -> UnderweightLowView Rating Details
7/21/2017Atlantic SecuritiesDowngradeNeutral -> Underweight$113.00LowView Rating Details
7/21/2017BTIG ResearchDowngradeNeutral -> Sell$110.00LowView Rating Details
7/12/2017Royal Bank Of CanadaReiterated RatingBuy$138.00MediumView Rating Details
7/6/2017Wells Fargo & CompanyReiterated RatingMarket Perform$132.00 -> $135.00LowView Rating Details
7/5/2017Morgan StanleyBoost Price TargetOverweight$135.00 -> $140.00LowView Rating Details
5/18/2017Stifel NicolausReiterated RatingHold -> Hold$124.00 -> $128.00LowView Rating Details
4/17/2017Barclays PLCReiterated RatingEqual Weight$125.00 -> $130.00LowView Rating Details
11/28/2016Bank of America CorporationReiterated RatingHold$126.00N/AView Rating Details
10/23/2016Societe GeneraleReiterated RatingHold$116.00N/AView Rating Details
10/21/2016ArgusReiterated RatingBuy$145.00N/AView Rating Details
9/11/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
8/19/2016Deutsche Bank AGReiterated RatingBuy$142.00N/AView Rating Details
5/20/2016Raymond James Financial, Inc.Reiterated RatingOutperform$120.00N/AView Rating Details
5/20/2016Standpoint ResearchInitiated CoverageSell$94.00N/AView Rating Details
4/20/2016Piper Jaffray CompaniesBoost Price TargetNeutral$105.00 -> $106.00N/AView Rating Details
1/27/2016Independent Research GmbHSet Price TargetNeutral$108.00N/AView Rating Details
10/15/2015S&P Equity ResearchReiterated RatingBuy$120.00N/AView Rating Details
(Data available from 9/23/2015 forward)


Earnings History for Johnson & Johnson (NYSE:JNJ)
Earnings by Quarter for Johnson & Johnson (NYSE:JNJ)
Earnings History by Quarter for Johnson & Johnson (NYSE JNJ)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/17/2017$1.79N/AView Earnings Details
7/18/2017Q2 2017$1.79$1.83$18.94 billion$18.84 billionViewN/AView Earnings Details
4/18/2017Q1 17$1.77$1.83$18.02 billion$17.77 billionViewN/AView Earnings Details
1/24/2017Q416$1.56$1.58$18.28 billion$18.10 billionViewN/AView Earnings Details
10/18/2016Q316$1.65$1.68$17.71 billion$17.80 billionViewListenView Earnings Details
7/19/2016Q216$1.68$1.74$17.98 billion$18.50 billionViewListenView Earnings Details
4/19/2016Q116$1.65$1.68$17.50 billion$17.50 billionViewListenView Earnings Details
1/26/2016Q415$1.42$1.44$17.88 billion$17.80 billionViewListenView Earnings Details
10/13/2015Q315$1.45$1.49$17.47 billion$17.10 billionViewListenView Earnings Details
7/14/2015Q215$1.69$1.71$17.76 billion$17.80 billionViewListenView Earnings Details
4/14/2015Q115$1.54$1.56$17.31 billion$17.37 billionViewListenView Earnings Details
1/20/2015Q414$1.25$1.27$18.59 billion$18.30 billionViewListenView Earnings Details
10/14/2014Q314$1.42$1.50$18.41 billion$18.50 billionViewListenView Earnings Details
7/15/2014Q214$1.54$1.66$18.86 billion$19.50 billionViewN/AView Earnings Details
4/15/2014Q114$1.48$1.54$18.00 billion$18.10 billionViewN/AView Earnings Details
1/21/2014Q413$1.20$1.24$17.95 billion$18.40 billionViewN/AView Earnings Details
10/15/2013Q313$1.32$1.36$17.46 billion$17.60 billionViewN/AView Earnings Details
7/16/2013Q2 2013$1.39$1.48$17.71 billion$17.90 billionViewN/AView Earnings Details
4/16/2013Q1 2013$1.41$1.44$17.46 billion$17.50 billionViewN/AView Earnings Details
1/22/2013Q4 2012$1.17$1.19$17.67 billion$17.60 billionViewN/AView Earnings Details
10/16/2012$1.21$1.25ViewN/AView Earnings Details
7/17/2012$1.29$1.30ViewN/AView Earnings Details
4/17/2012$1.34$1.37ViewN/AView Earnings Details
1/24/2012$1.09$1.13ViewN/AView Earnings Details
10/18/2011$1.21$1.24ViewN/AView Earnings Details
7/19/2011$1.24$1.28ViewN/AView Earnings Details
4/19/2011$1.26$1.35ViewN/AView Earnings Details
1/25/2011$1.03$1.03ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Johnson & Johnson (NYSE:JNJ)
2017 EPS Consensus Estimate: $7.07
2018 EPS Consensus Estimate: $7.90
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$1.71$1.77$1.74
Q2 20172$1.75$1.86$1.81
Q3 20171$1.84$1.84$1.84
Q4 20171$1.68$1.68$1.68
Q1 20181$2.01$2.01$2.01
Q2 20181$2.03$2.03$2.03
Q3 20181$1.99$1.99$1.99
Q4 20181$1.87$1.87$1.87
(Data provided by Zacks Investment Research)


Current Dividend Information for Johnson & Johnson (NYSE:JNJ)
Most Recent Dividend:9/12/2017
Annual Dividend:$3.36
Dividend Yield:2.56%
Dividend Growth:6.70% (3 Year Average)
Payout Ratio:56.76% (Trailing 12 Months of Earnings)
46.80% (Based on This Year's Estimates)
43.47% (Based on Next Year's Estimates)
Track Record:54 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Johnson & Johnson (NYSE:JNJ)

Dividend History by Quarter for Johnson & Johnson (NYSE JNJ)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Johnson & Johnson (NYSE:JNJ)
Insider Ownership Percentage: 0.19%
Institutional Ownership Percentage: 65.90%
Insider Trades by Quarter for Johnson & Johnson (NYSE:JNJ)
Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)
Insider Trades by Quarter for Johnson & Johnson (NYSE:JNJ)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/24/2017Paulus StoffelsVPSell102,692$133.14$13,672,412.88View SEC Filing  
7/20/2017Dominic J CarusoVPSell82,591$136.72$11,291,841.52View SEC Filing  
2/15/2017Paulus StoffelsVPSell22,000$117.29$2,580,380.00View SEC Filing  
10/21/2016Charles PrinceDirectorBuy875$114.11$99,846.25View SEC Filing  
7/26/2016Dominic J CarusoVPSell41,146$125.01$5,143,661.46View SEC Filing  
7/22/2016Ronald A KapustaCAOSell2,935$125.01$366,904.35View SEC Filing  
6/7/2016Gary J PrudenVPSell9,735$116.03$1,129,552.05View SEC Filing  
6/7/2016Ronald A KapustaCAOSell3,000$115.79$347,370.00View SEC Filing  
5/10/2016Ronald A KapustaCAOSell3,957$114.77$454,144.89View SEC Filing  
2/17/2016Paulus StoffelsinsiderSell125,000$102.43$12,803,750.00View SEC Filing  
2/3/2016Peter FasoloVPSell151,385$104.12$15,762,206.20View SEC Filing  
10/23/2015Ronald A. KapustaCAOSell6,239$99.68$621,903.52View SEC Filing  
6/2/2015Charles PrinceDirectorBuy2,500$99.22$248,050.00View SEC Filing  
4/28/2015Paulus StoffelsInsiderSell187,250$100.73$18,861,692.50View SEC Filing  
9/10/2014James CullenDirectorSell2,446$104.12$254,677.52View SEC Filing  
5/5/2014Stephen CosgroveInsiderSell22,000$100.05$2,201,100.00View SEC Filing  
3/14/2014Peter FasoloVPSell6,824$93.15$635,655.60View SEC Filing  
8/14/2013Stephen CosgroveInsiderSell17,200$91.39$1,571,908.00View SEC Filing  
8/5/2013Michael UllmannVPSell16,140$93.68$1,511,995.20View SEC Filing  
7/25/2013Paulus StoffelsInsiderSell45,440$92.40$4,198,656.00View SEC Filing  
7/18/2013Dominic J CarusoCFOSell30,000$90.31$2,709,300.00View SEC Filing  
11/12/2012James CullenDirectorSell13,900$69.70$968,830.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Johnson & Johnson (NYSE:JNJ)
Latest Headlines for Johnson & Johnson (NYSE:JNJ)
DateHeadline logoJohnson & Johnson Sees Unusually High Options Volume (JNJ) - September 23 at 1:02 AM logoPfizer is suing Johnson & Johnson, saying it prevented uptake of cheaper Remicade rival - September 22 at 6:52 PM logoJohnson & Johnson Innovation announces winners of the Singapore QuickFire Challenge in collaboration with ETPL and SMART - September 22 at 6:52 PM logoSEE IT: Johnson & Johnson heiress tries to kick horse in Hamptons - September 22 at 6:52 PM logoJohnson & Johnson heiress Jazz Johnson-Merton caught kicking horse on video? - September 22 at 6:52 PM logoJohnson & Johnson : JNJ-US: Dividend Analysis : August 29th, 2017 (record date) : By the numbers : September 21, 2017 - September 22 at 6:52 PM logoJ&J Was Alerted to Risk of Asbestos in Talc in ’70s, Files Show - September 22 at 6:52 PM logoJohnson & Johnson breached its 50 day moving average in a Bearish Manner : JNJ-US : September 22, 2017 - September 22 at 6:52 PM logoBetter Buy: Kimberly-Clark Corp. vs. Johnson & Johnson - September 22 at 6:52 PM logoU.S. FDA rejects J&J's arthritis drug - September 22 at 6:52 PM logoFDA declines to approve J&J arthritis drug sirukumab - September 22 at 6:52 PM logoJohnson & Johnson Acquires Sightbox For Contact Lens Subscriptions - Seeking Alpha - September 22 at 12:07 PM logoDow 30 Stock Roundup: BA Wins $600M Air Force Contract, JPM Invests in - September 22 at 12:07 PM logoWhat Pfizer’s Valuation Changes after 2Q17 Tell Us - September 22 at 12:07 PM logoResearch Shows That Canadian Military Servicemembers and First Responders Struggle to Get Support for Their Own Health Needs - September 21 at 3:39 PM logoJ&J? It’s Time to Sell on Valuation: Goldman Sachs - September 21 at 3:39 PM logoJohnson & Johnson Stock Sinks, Goldman Downgrades to 'Sell' - - September 21 at 9:21 AM logoPfizer accuses Johnson & Johnson of 'anticompetitive practices' in lawsuit - USA TODAY - September 21 at 9:21 AM logoThis squabble between two big drugmakers could have major implications for the U.S. health care system - September 21 at 9:21 AM logoPfizer accuses Johnson & Johnson of 'anticompetitive practices' in lawsuit - USA TODAY - September 20 at 11:53 PM logo[$$] Pfizer Alleges J&J Thwarted Competition to Remicade, in Legal Test of Biotech-Drug Copies - September 20 at 11:53 PM logo[$$] The Murky World of Drug Rebates Gets Airing in Lawsuit - September 20 at 11:53 PM logoPfizer and Johnson & Johnson's Brewing Brawl Gets Real - September 20 at 11:53 PM logoPfizer and Johnson & Johnson's Brewing Brawl Gets Real - September 20 at 8:52 PM logoJohnson & Johnson (JNJ) Lowered to Sell at Goldman Sachs Group, Inc. (The) - September 20 at 9:46 AM logoSell Johnson & Johnson because of its 'stretched' valuation: Goldman - September 20 at 9:37 AM logoJohnson & Johnson's Dividend Will Continue To Chug Along, But Likely At A Slower Pace - September 19 at 8:16 PM logoCrazy Weak U.S. Dollar Will Make These 10 Companies Huge Winners - September 19 at 8:16 PM logoThe only thing Trump is doing to end the opioid crisis rewards the companies that started it - September 19 at 8:15 PM logo[$$] Johnson & Johnson Acquires Contact Lens Service Sightbox - September 19 at 8:15 PM logoInteresting June 2018 Stock Options for JNJ - Nasdaq - September 19 at 5:42 AM logoJohnson & Johnson (JNJ) Subsidiary Janssen Research Reports ... - - September 19 at 5:42 AM logoPortland's Sightbox sold to health care behemoth - Portland Business Journal - September 19 at 5:42 AM logoJohnson & Johnson (JNJ) Stock Rating Lowered by Vetr Inc. - September 19 at 12:48 AM logoJohnson & Johnson (JNJ) Subsidiary Janssen Research Reports New Two-Year TREMFYA (Guselkumab) Data - September 18 at 7:39 PM logoNeos Therapeutics ADHD Drug Adzenys Receives Approval in US - September 18 at 7:39 PM logoPortland's Sightbox sold to health care behemoth - September 18 at 7:39 PM logo10 Rock-Solid Reasons Johnson & Johnson's Near-Term Future Looks Bright - September 17 at 7:09 PM logo10 Rock-Solid Reasons Johnson & Johnson's Near-Term Future Looks Bright - September 17 at 9:22 AM logoJohnson & Johnson (JNJ) Given Consensus Recommendation of "Hold" by Analysts - September 17 at 6:38 AM logoEuropean panel recommends approval of J&J's psoriasis drug - September 16 at 2:53 AM logoEuropean panel backs Janssen's psoriasis drug - September 16 at 2:52 AM logoJohnson & Johnson Is Getting Ready for Another Upside Breakout - September 16 at 2:52 AM logoPfizer Xtandi Succeeds in Early Stage Prostate Cancer Study - September 16 at 2:52 AM logo[$$] JNJ May Benefit From Celltrion Issues - September 16 at 2:52 AM logoPfizer Punches Back at Johnson & Johnson in Prostate Cancer - September 15 at 8:16 AM logoAchillion Is Crushed As Johnson & Johnson Heads For The Exit - Seeking Alpha - September 15 at 2:57 AM logoJohnson & Johnson to Host Investor Conference Call on Third-Quarter Results - September 15 at 2:57 AM logoETFs with exposure to Johnson & Johnson : September 14, 2017 - September 15 at 2:57 AM logoCramer's No. 1 rule for spotting market rotations - September 15 at 2:57 AM



Johnson & Johnson (JNJ) Chart for Saturday, September, 23, 2017

This page was last updated on 9/23/2017 by Staff